

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Suvorexant

March 17, 2026

Therapeutic category

Other agents affecting central nervous system

Non-proprietary name

Suvorexant

Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.
 This English version is intended to be a reference material to provide convenience for users.
 In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current			Revision		
2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) 2.2 Patients receiving the following drugs: Itraconazole, posaconazole, voriconazole, clarithromycin, vonoprazan/amoxicillin/clarithromycin, rabeprazole/amoxicillin/clarithromycin, ritonavir, nirmatrelvir/ritonavir, ensitrelvir			2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) 2.2 Patients receiving the following drugs: Itraconazole, posaconazole, voriconazole, clarithromycin, vonoprazan/amoxicillin/clarithromycin, rabeprazole/amoxicillin/clarithromycin, ritonavir, nirmatrelvir/ritonavir, ensitrelvir, <u>ceritinib</u>		
10. INTERACTIONS 10.1 Contraindications for Co-administration (Do not co-administer with the following.)			10. INTERACTIONS 10.1 Contraindications for Co-administration (Do not co-administer with the following.)		
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
Itraconazole Posaconazole Voriconazole Clarithromycin Vonoprazan/amoxicillin/clarithromycin Rabeprazole/amoxicillin/clarithromycin Ritonavir Nirmatrelvir/ritonavir Ensitrelvir	These drugs may markedly enhance the effects of this drug.	These drugs strongly inhibit CYP3A, a metabolic enzyme of suvorexant, and markedly increase the plasma concentration of suvorexant.	Itraconazole Posaconazole Voriconazole Clarithromycin Vonoprazan/amoxicillin/clarithromycin Rabeprazole/amoxicillin/clarithromycin Ritonavir Nirmatrelvir/ritonavir Ensitrelvir <u>Ceritinib</u>	These drugs may markedly enhance the effects of this drug.	These drugs strongly inhibit CYP3A, a metabolic enzyme of suvorexant, and markedly increase the plasma concentration of suvorexant.